Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes
Rabih R. Azar, MD, MSra,
Raymond G. McKay, MD, FACCa,
Paul D. Thompson, MD, FACCa,
Jeffrey A. Hirst, MD, FACCa,
Joseph F. Mitchell, DO, FACCa,
Daniel B. Fram, MD, FACCa,
David D. Waters, MD, FACCa and
Francis J. Kiernan, MD, FACCa
a Division of Cardiology, Hartford Hospital and the University of Connecticut School of Medicine, Hartford, Connecticut, USA
View larger version (13K):
[in a new window]
|
Figure 1 Event-free survival during the total follow-up period. The y axis represents the percentage of patients without an event at the time of follow-up (x axis). The number and percentage of patients assessed at each time interval are shown below the x axis. *p < 0.01; **p < 0.05.
|
|
View larger version (16K):
[in a new window]
|
Figure 2 Event-free survival in the four subgroups of treatment. The y axis represents the percentage of patients without an event at the time of follow-up (x axis). The number and percentage of patients assessed at each time interval are shown below the x axis. *p < 0.01; **p = 0.07 compared to no stent, no infusion.
|
|
|
